Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Mar 2018A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

Groupe Francophone des Myelodysplasies — PHASE3

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

Rytelo

Geron Corporation

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Rytelo

(IMETELSTAT SODIUM)Orphan drugstandard

Geron Corporation

12.1. Mechanism of Action Imetelstat is an oligonucleotide human telomerase inhibitor that binds to the template region of the RNA component of human ...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

1 active trial
1Phase 3
1Total recruiting
Search clinical trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Recent News & Research

No recent news articles indexed yet for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality.
Search PubMed for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Browse all Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality news →

Specialist Network

Top 6 by expertise

View all Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality specialists →

Quick Actions